-
US lays it on the line as WTO mulls future of global trading
-
Joy, scepticism across west Africa after UN vote on slave trade
-
Salah would be 'asset' says San Diego FC owner
-
Parmesan exports doing grate... but sales melt in Italy
-
US cannot meet Iran war-induced LNG shortfall: industry leaders
-
Trump denies being 'desperate' for Iran deal
-
US envoy to UK warns against cancelling king's visit
-
IOC's new gender testing throws up multiple questions
-
Malinin back to his best as third world skating title beckons
-
Cuban children's heart hospital makes tough choices amid US blockade
-
Oil climbs, stocks slide on uncertainty over US-Iran talks
-
Nepal's PM-to-be delivers first post-election message in rap, urges unity
-
Vernon wins wind-hit Tour of Catalonia stage as Pidcock climbs to second
-
ChatGPT's taste for literary nonsense sparks alarm
-
Paul McCartney recalls Yesterday with first album in five years
-
'True miracle': Napoleon's long-lost hat to go on display
-
Lost in space: Sperm struggles to navigate during weightless sex
-
G7 meets in France hoping to heal transatlantic Iran rift
-
IOC's gender test directive throws up multiple questions
-
Trump insists Iran operations 'extremely' ahead of schedule
-
Bab al-Mandeb Strait: another key shipping route under threat
-
Families of Kabul bombing victims still search for answers
-
Police detain French ex-cop suspected of killing mothers of his children
-
Venezuela's Maduro back in court after stunning US capture
-
Senegal victims of 'most blatant scam' in football history: federation
-
Former badminton Olympic gold winner Marin retires due to injury
-
Olympic women's sport to be limited to biological females
-
Africa sets out stall for cotton at the WTO
-
Trump's Iran war tests MAGA 'America First' creed
-
What's happening with Iran-US 'talks'?
-
WTO mulls future of global trading under cloud of Mideast war
-
US flexes 'new order' trade policy as WTO meet kicks off
-
Germany unveils rescue plan for struggling chemical sector
-
UK PM 'very keen' to curb addictive social media after US ruling
-
South Africa disinvited from G7 in France after US pressure: Pretoria
-
EU moves closer to ban sexualised AI deepfakes
-
France bids farewell to ex-PM Jospin who 'modernised' nation
-
Belarus' Lukashenko gifts automatic rifle to North Korea's Kim
-
Germany bank on team spirit to end World Cup woes
-
Venezuela's Maduro back in US court after stunning capture
-
French court orders ex-bishop to pay over 1970s child sex abuse
-
PSG Ligue 1 game postponed in between two legs of Liverpool Champions League tie
-
Iran may believe it has the upper hand as Trump seeks talks
-
EU urged to broadly restrict 'forever chemicals'
-
Italy seizes millions 'embezzled' from Ursula Andress
-
Trump says Iran 'better get serious' in Mideast war talks
-
Global trading system hit by 'worst disruptions in the past 80 years': WTO chief
-
Oil jumps, stocks drop on uncertainty over US-Iran talks
-
EU accuses four porn platforms of letting children access adult content
-
Cathay Pacific raises fuel surcharge on all flights by 34%
Man who let snakes bite him 200 times spurs new antivenom hope
Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him.
Four days later, he woke up from a coma.
"I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin.
This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time.
From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times.
Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home.
After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists.
But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom.
The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom.
This would fill a major need, because currently most antivenoms only cover one or a few of the world's 600 venomous snakes.
Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization.
These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas.
- 'Pain every time' -
Friede's first bite was from a harmless garter snake when he was five years old.
"I was afraid, I cried, I ran away," said Friede, now 57.
Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted.
Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom.
How antivenom is made has changed little over the last 125 years.
Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom.
However this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from horse that can cause serious side-effects including anaphylactic shock.
"I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said.
He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes.
"There is pain every time," he said.
- 'Proud' -
For years, the scientists he contacted to take advantage of his immunity refused to bite.
Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom.
Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites.
When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood."
"I've been waiting for this call for a long time," came the response, Glanville said.
The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib.
It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six.
The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia.
Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies.
Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down.
Friede said he was "proud" to have made a "small difference" in medical history.
Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues.
But he hopes to get bitten by snakes again in the future.
"I do miss it," he said.
M.AbuKhalil--SF-PST